- LOGIN
- MemberShip
- 2020-10-24 11:50
Dailypharm Korea will be available without login access until the end of December 2019.
Membership login access would be required from February 2020 to access more news and website services.
Membership login access would be required from February 2020 to access more news and website services.
- Company
- “Access to Onivyde should improve for more options"
- by Aug 26, 2020 06:23am
- “Besides the findings from global clinical study on treating metastatic pancreatic cancer patients, Onivyde even offers subset analysis on Asian patients and real-world evidence (RWE) in South Korea. It is regretful the treatment has not been listed for National Health Insurance (NHI) reimbursement.” On Aug. 20, Professor Yoo Chang-hoo
- Company
- ↓generic's approval as the drug price system is implemented
- by Chon, Seung-Hyun Aug 26, 2020 06:22am
- The number of approval for generic drugs has declined for the second consecutive month. If the bioequivalence test is not performed, the new drug price system, which gives low drug prices, was implemented, and greatly reduced the number of new licenses for authorized generics. Some point out that the government's move to strengthen generic regul
- Company
- There is still misinformation and choice regarding MPHL
- by Eo, Yun-Ho Aug 25, 2020 06:14am
- The male-type hair loss treatment'Propecia (finasteride 1mg)' was introduced in Korea, and hair loss was treated in earnest in 2000. Propecia identified the correlation between type II 5-alpha reductase and male pattern hair loss, suggested the therapeutic potential of male pattern hair loss, which was considered an incurable hereditary d
- Company
- Celltrion begins to develop oral Remsima following SC type
- by Kim, Jin-Gu Aug 24, 2020 06:19am
- Celltrion starts developing oral 'Remsima'. Celltrion announced on the 20th that it has signed a joint research agreement with British biotechnology company Intract Pharma. Remicade, Remsima's original drug, is a drug administered by intravenous injection.. Celltrion has already developed and commercialized Remsima SC, the first in the wor
- Company
- United promotes phase III tx for COVID-19 in the Philippines
- by Aug 24, 2020 06:18am
- Korea United Pharmaceutical (CEO Kang Deok-young) is starting to develop a cure for COVID-19. It is Drug Repositioning of the company's Incrementally Modified Drug 'UI030'. United said on the 19th, "UI030 has confirmed the antiviral effect of up to 30 times compared to Ciclesonide in cell experiments." According to the company, UI030 is
- Company
- Patent dispute for Promac, eventually to Supreme Court
- by Kim, Jin-Gu Aug 24, 2020 06:18am
- The patent dispute over the anti-ulcer drug, Promac (Polaprezinc) was finally concluded in the Supreme Court. According to the pharmaceutical industry on the 19th, SK Chemical, which holds a formulation patent for Promac, recently filed an appeal to the Supreme Court against Hana Pharm and Korea Prime. Earlier, on the 17th of last month
- Company
- Drug industry back on full alert as COVID-19 cases resurge
- by Aug 21, 2020 06:26am
- The pharmaceutical industry is on full alert again as the confirmed cases of novel coronavirus infection (COVID-19) is resurging rapidly around Seoul metropolitan area. Some companies have already reinitiated emergency working system with employees working in shifts or from home. The South Korean government has recently decided to toughen th
- Company
- Companies are worried about a sharp decline in Rx drug sales
- by Chon, Seung-Hyun Aug 20, 2020 06:24am
- Pharmaceutical companies are again tense with COVID-19. The prescription drug market suffered a temporary sluggishness due to the aftermath of COVID-19, and while it is recovering, the market has contracted again and is worried. Business activities can be greatly affected by the spread of telecommuting. According to UBIST on the 19th, the tot
- Company
- Big 5 except Severance clear Novartis’ Kisqali prescription
- by Eo, Yun-Ho Aug 19, 2020 06:28am
- South Korean general hospitals are ready to prescribe a third cyclin-dependent kinase (CDK) 4/6 inhibitor Kisqali approved after Ibrance and Verzenio. According to the related industry sources, Novartis’ Kisqali (ribocilib) has passed drug committees (DC) at all Big Five general hospitals&8212;Samsung Medical Center, Seoul National Uni
- Company
- Daewoong signs an export contract for Fexuprazan
- by Kim, Jin-Gu Aug 19, 2020 06:28am
- Daewoong announced on the 14th that it has signed an export contract with EMS in Brazil for the P-CAB-affiliated gastric secretion inhibitor Fexuprazan. The contract amount is $72.58 million. EMS will be responsible for the local approval of Fexuprazan in Brazil. The export is expected to proceed in earnest after obtaining permission to B
